Lowering blood pressure target to reduce noradrenaline use in cardiogenic shock patients
Official title: Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction
Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT05168462 · Data updated 2026-11-12
This study is testing if aiming for a lower blood pressure target can help patients in cardiogenic shock use less medication and improve their chances of survival and kidney health.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 776 (estimated) |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 1 site (Amsterdam) |
| Status | Recruiting |
| Started | October 1, 2022 |
| Main results expected | April 1, 2027 |
| Study ends | April 1, 2028 |
| Registry record updated | March 27, 2026 |
| Trial ID | NCT05168462 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with acute myocardial infarction who are experiencing cardiogenic shock and meet specific clinical criteria.
✕Probably not a fit
Patients with mechanical causes of cardiogenic shock or those requiring immediate mechanical circulatory support may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effectiveness and cost-effectiveness of using a lower mean arterial pressure (MAP) target of ≥ 55 mmHg compared to ≥ 65 mmHg in patients experiencing cardiogenic shock due to acute myocardial infarction. The study aims to determine if reduced use of the vasopressor noradrenaline can improve survival rates and decrease the incidence of renal failure. Participants will be closely monitored for clinical signs of organ perfusion and overall outcomes related to their treatment. The trial is conducted at the Amsterdam UMC, focusing on patients who meet specific inclusion criteria related to their condition.
Why it matters
Potential benefit: If successful, this approach could lead to improved survival rates and reduced complications for patients with cardiogenic shock.
How similar studies have gone: Other studies have explored similar approaches, but this specific methodology of targeting a lower MAP in cardiogenic shock is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: 1. Acute myocardial infarction, STEMI or NSTEMI 2. Early revascularization by PCI 3. Cardiogenic shock, characterized by: I. a. Systolic blood pressure (SBP) ≤ 90 mmHg for \> 30 minutes, OR b. Use of drugs to maintain SBP \> 90 mmHg at randomization. II. Clinical signs of impaired organ perfusion with at least one of the following criteria: 1. Altered mental status 2. Cold, clammy skin and extremities 3. Oliguria with urine output \< 30ml/hour 4. Serum lactate \> 2.0 mmol/L III. Clinical signs of pulmonary congestion Exclusion Criteria: 1. Resuscitation \> 30 minutes 2. Mechanical cause of cardiogenic shock (e.g. papillary muscle rupture, ventricular septal rupture) 3. Onset of shock \> 12 hours 4. Imminent need for mechanical circulatory support (i.e. ECPR) 5. Women \<45 years
Where it's running
-
Amsterdam UMC, location AMC
Amsterdam, Netherlands Recruiting
Study contacts
- Study coordinator: Elma Peters
- Email: e.j.peters@amsterdamumc.nl
- Phone: 0205668380
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Efferon CT hemoadsorption for cardiogenic shock after a heart attack
This trial will test whether using the Efferon CT blood‑filtering device in patients who develop cardiogenic shock within hours of a heart attack can lower harmful inflammation and help prevent organ failure.
-
Heart@Home: Safe, at-home care for people with acute heart problems compared with hospital care
This trial tests whether hospital-level care at home can safely and effectively treat adults with acute heart conditions who would normally be in the hospital.
-
Factors Influencing Outcomes in ECMO and Impella Patients
This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.
-
Digital cardiac rehab to help heart attack patients improve function
A digital health–supported cardiac rehabilitation program is being tested to see if it helps people after a heart attack improve fitness and stay engaged with rehab, compared with standard outpatient rehab.
-
Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients
This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.
-
NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa
This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.